Therapeutic options for ALK-positive NSCLC involve ALK inhibitors crizotinib (XALKori, Pfizer), brigatinib (ALUNBRIG, Takeda Pharma), and ceritinib (Zykadia, Novartis Europharm) [8,14]. Here, ALK is linked to non-small cell lung carcinoma.